Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study

Table 6 Beta-defensin-1 haplotypes and infection outcomes.

Haplotype	Physician visits‡§	Part 1 p Value*	Part 2 p Value†	Days in bed‡ll	Part 1 p Value*	Part 2 p Value†
ACA	0.26 (0.08)	0.84	0.88	0.60 (0.19)	0.40	0.10
GCA	0.27 (0.03)			0.50 (0.06)
GGA	0.50 (0.27)			2.50 (0.63)
ACG	0.28 (0.02)			0.50 (0.06)
GCG	0.45 (0.11)			1.00 (0.27)
AGG	0.23 (0.20)			0.60 (0.48)
GGG	0.24 (0.04)			0.36 (0.08)

*Part 1 of the two-part model involves modeling whether an individual has any physician visits or any days in bed due to lower respiratory infection. P values derived from the Wald statistic based on logistic regression results from Hapassoc. Decline in lung function status was included as a factor in the analysis.
†Part 2 of the two-part model involves modeling the average number of physician visits or days in bed due to lower respiratory infection given that it is greater than zero. P values derived from the Wald statistic based on gamma regression results from Hapassoc. Decline in lung function status was included as a factor in the analysis.
‡Mean (SE).
§Mean number of visits to a physician for lower respiratory infections per year.
llMean number of days kept in bed for lower respiratory infections per year.

ISSN: 1465-993X